This WilmerHale webinar series is designed to provide pharmaceutical companies with a detailed overview of the new Food & Drug Administration Amendments Act of 2007, a forecast of its impact on all aspects of regulatory compliance and product development, as well as practical tips to prepare for implementation of the new regulatory requirements.
In this third session, topics of discussion will include clinical trial databank expansion and potential policy issues.